Home Other Building Blocks 5355-16-8
5355-16-8,MFCD00057349
Catalog No.:AA01CBKH

5355-16-8 | Diaveridine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$7.00   $5.00
- +
250mg
98%
in stock  
$13.00   $9.00
- +
1g
98%
in stock  
$32.00   $22.00
- +
5g
98%
in stock  
$91.00   $64.00
- +
25g
98%
in stock  
$307.00   $215.00
- +
100g
98%
in stock  
$871.00   $610.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA01CBKH
Chemical Name:
Diaveridine
CAS Number:
5355-16-8
Molecular Formula:
C13H16N4O2
Molecular Weight:
260.2917
MDL Number:
MFCD00057349
SMILES:
COc1cc(ccc1OC)Cc1cnc(nc1N)N
Properties
Properties
 
BP:
506.1°C  
Form:
Solid  
MP:
233°  
Storage:
Inert atmosphere;2-8℃;  

Computed Properties
 
Complexity:
279  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
19  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
4  
XLogP3:
1  

Downstream Synthesis Route

[1]Patent:US2658897,1951,

[1]JournaloftheAmericanChemicalSociety,1951,vol.73,p.3758,3760

[2]Patent:US2624732,1950,

[1]Arzneimittel-Forschung/DrugResearch,1988,vol.38,p.1778-1783

Literature

Title: Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.

Journal: Scientific reports 20180101

Title: Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.

Journal: Journal of medicinal chemistry 20040115

Title: Mutagenic activity and mutational specificity of antiprotozoal drugs with and without nitrite treatment.

Journal: Environmental and molecular mutagenesis 20020101

Title: Adaptive neuro-fuzzy inference system: an instant and architecture-free predictor for improved QSAR studies.

Journal: Journal of medicinal chemistry 20010816

Title: In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii.

Journal: The Journal of antimicrobial chemotherapy 19981001

Title: Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.

Journal: Annals of tropical medicine and parasitology 19961201

Title: Fine structural specificity differences of trimethoprim allergenic determinants.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 19961001

Title: Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Journal: Antimicrobial agents and chemotherapy 19920901

Title: [Synthesis and antimycobacterial action of lipophilic substituted 2,4-diamino-5-benzylpyrimidines].

Journal: Arzneimittel-Forschung 19881201

Title: 5-BENZYL-2,4-DIAMINOPYRIMIDINES AS ANTIBACTERIAL AGENTS. I. SYNTHESIS AND ANTIBACTERIAL ACTIVITY IN VITRO.

Journal: Journal of medicinal and pharmaceutical chemistry 19621101

Title: Sirichaiwat C et al. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem 47:345-54 (2004).

Title: Ono T, et al. The genotoxicity of diaveridine and trimethoprim. Environ Toxicol Pharmacol. 1997 Sep;3(4):297-306.

Title: Wang J, et al. Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents. Environ Toxicol Pharmacol. 2015 Sep;40(2):660-70.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:5355-16-8 Molecular Formula|5355-16-8 MDL|5355-16-8 SMILES|5355-16-8 Diaveridine